HPLC法同时测定保健食品中6种大豆异黄酮类成分的含量

目的:建立同时测定大豆类保健食品中大豆苷、黄豆黄苷、染料木苷、大豆苷元、黄豆黄素、染料木素6种成分含量的高效液相色谱法。方法:色谱柱为 Agilent Zorbax SB-C_(18)(4.6 mm×150 mm,5 μm),采用流动相乙腈-0.2%甲酸进行梯度洗脱,流速为1 mL·min~(-1),检测波长为255 nm。结果:大豆苷、黄豆黄苷、染料木苷、大豆苷元、黄豆黄素、染料木素的线性范围分别为0.42～3.15,0.20～2.25,0.41～3.06,0.15～1.14,0.051～0.38,0.21～1.55 μg;加样回收率(n=5)分别为95.86%,96.87%,96.85%,96.63%,96.48%,96.67%。结论:本方法简便、灵敏、准确,可用于含大豆异黄酮类保健食品中以上6种成分的含量测定和产品质量控制。     

大豆总异黄酮的提取及含量测定

目的建立大豆总异黄酮的提取方法及含量测定方法.方法以大豆为原料通过乙醇浸泡提取,聚酰胺柱层析提取大豆总异黄酮.并用HPLC法测定大豆总异黄酮含量.结果提取物物大豆总异黄酮含量为52.26%.HPLC的条件为:C18柱,流动相为甲醇∶水∶乙酸=42∶57∶1,检测波长为260 nm.结论提取方法简单,测定方法简便、快捷,重现性好,可用于大豆总异黄酮的含量测定.     

超高效液相色谱法测定大豆异黄酮胶囊中异黄酮的含量

目的建立同时测定大豆异黄酮胶囊中6种异黄酮含量的超高效液相色谱法(HPLC)。方法采用AcquityUPLCTMBEHC18柱(1.7μm,2.1mm×50mm),流动相为甲醇-0.05mol/L乙酸胺(pH4.6),梯度洗脱,检测波长为260nm,流速为0.4ml/min,柱温为40℃,外标法测定。结果大豆苷、黄豆黄苷、染料木苷、大豆苷元、黄豆黄素和染料木素分别在0.02600～0.2600mg/ml、0.02625～0.2625mg/ml、0.02675～0.2675mg/ml、0.012650～0.12650mg/ml、0.012525～0.12525mg/ml、0.012750～0.12750mg/ml范围内线性关系良好(r≥0.9930),加样回收率(6例)分别为:98.5%、98.8%、98.2%、97.7%、98.0%、97.3%。结论本法快速、简便、准确、灵敏度高、成本低,适用于大豆异黄酮胶囊中异黄酮的含量测定及质量控制。     

大豆总异黄酮的提取及含量测定

目的建立大豆总异黄酮的提取方法及含量测定方法。方法以大豆为原料通过乙醇浸泡提取,聚酰胺柱层析提取大豆总异黄酮。并用HPLC法测定大豆总异黄酮含量。结果提取物物大豆总异黄酮含量为52.26%。HPLC的条件为:C18柱,流动相为甲醇∶水∶乙酸=42∶57∶1,检测波长为260 nm。结论提取方法简单,测定方法简便、快捷,重现性好,可用于大豆总异黄酮的含量测定。     

大豆总异黄酮的提取及含量测定

目的建立大豆总异黄酮的提取方法及含量测定方法。方法以大豆为原料通过乙醇浸泡提取，聚酰胺柱层析提取大豆总异黄酮。并用HPLC法测定大豆总异黄酮含量。结果提取物物大豆总异黄酮含量为52．26％。HPLC的条件为：C18柱，流动相为甲醇：水：乙酸=42：57：1，检测波长为260nm。结论提取方法简单，测定方法简便、快捷，重现性好，可用于大豆总异黄酮的含量测定：     

RP-HPLC法同时测定怀槐树皮中4种异黄酮苷的含量

目的建立HPLC同时测定怀槐树皮药材中染料木苷、鸢尾苷、saikoisoflavonoside A和怀槐异黄酮苷含量的方法。方法色谱柱为Diamonsil^(TM)ODS(250 mm×4.6 mm,5μm);流动相为乙腈-质量分数为0.05%磷酸溶液(体积比为16:84);流速为1.0 mL·min(TM)ODS(250 mm×4.6 mm,5μm);流动相为乙腈-质量分数为0.05%磷酸溶液(体积比为16:84);流速为1.0 mL·min^(-1);检测波长为260 nm;柱温为35℃。结果染料木苷、鸢尾苷、saikoisoflavonoside A和怀槐异黄酮苷的质量浓度分别在0.42～2.09、1.00～5.00、5.12～25.60和1.81～9.04 mg·L(-1);检测波长为260 nm;柱温为35℃。结果染料木苷、鸢尾苷、saikoisoflavonoside A和怀槐异黄酮苷的质量浓度分别在0.42～2.09、1.00～5.00、5.12～25.60和1.81～9.04 mg·L^(-1)内与峰面积线性关系良好,平均回收率分别为99.4%、99.9%、100.2%和99.9%,RSD分别为2.1%、3.0%、2.5%和2.7%。结论该方法可用于怀槐树皮中染料木苷、鸢尾苷、saikoisoflavonoside A和怀槐异黄酮苷的含量测定。     

高效液相色谱法测定赤芍中赤芍总苷的含量

目的研究用高效液相色谱法测定赤芍总苷(TPG)含量的可行性.方法赤芍经70%乙醇提取后大孔吸附树脂分离以制备TPG;采用高效液相色谱法(HPLC)测定赤芍总苷中芍药苷含量,色谱条件:S-Gel C18,5 μm色谱柱,流动相:甲醇-水(50∶ 50),柱温40℃,流速0.8 ml·min-1,检测波长230 nm.结果大孔吸附树脂分离赤芍总苷(TPG)的制备工艺质量稳定;HPLC法准确、可靠、重现性好,平均回收率为100.1%,RSD为1.96%.结论建立的方法可用以控制赤芍总苷质量.     

HPLC测定消痤颗粒中黄芩苷的含量

目的　建立测定消痤颗粒中黄芩苷的含量测定方法。方法　采用HPLC法 ,SupelcosilTMLC - 18色谱柱 (4 6mm× 2 5 0mm ,5 μm) ,流动相为甲醇 - 0 2 %磷酸水溶液 (4 7∶5 3) ;流速 1 0ml·min- 1 ;检测波长 2 80nm ;柱温 35℃。结果　黄芩苷在 0 0 30 6- 0 0 918μg范围内线性关系良好 (r=0 9997)。方法回收率为 10 0 5 % ,RSD在 0 98% - 1 6 %范围内 (n =5 )。 结论　此方法简便、快速、准确 ,分离效果好 ,可作为消痤颗粒的主要质控指标。     

HPLC法测定银黄片中黄芩苷的含量

目的 建立测定银黄片中黄芩苷的含量测定方法.方法HPLC法,采用Shimadzu C18柱(150 mm× 4.6 mm,5 μm);流动相为甲醇-水-冰醋酸(45:55:1);流速为1.0 ml·min-1.拄温为40 ℃.检测波长为274 nm.结果 黄芩苷在2.072～10.360 μg范围内呈良好线性关系,r=0.9996;平均回收率为97.87%,RSD为0.55%.结论 所建立的方法可准确、快速地测定银黄片中黄芩苷的含量,可用于该制剂的质量控制.     

HPLC法测定升白合剂中芍药苷的含量

目的:建立HPLC法测定升白合剂中芍药苷含量的方法.方法:色谱柱:Alltech C18柱(150 mm×4.6 mm,5 μm);流动相为甲醇-水(27∶73);流速为1.0 mL*min-1;检测波长为230 nm.结果:以高效液相色谱法测定,芍药苷进样量在1.043～8.344 μg范围内的线性关系良好(r＝1),平均加样回收率99.3%,RSD为0.8%(n＝6).结论:本法操作简便、准确,重复性好,可作为该制剂的质量控制标准.     

Synthesis,Cytotoxicity and Antileishmanial Activity of Some N-(2-(indol-3-yl)ethyl)-7-chloroquinolin-4-amines

We report herein the condensation of 4,7-dichloroquinoline (1) with tryptamine (2) and D-tryptophan methyl ester (3) . Hydrolysis of the methyl ester adduct (5) yielded the free acid (6) . The compounds were evaluated in vitro for activity against four different species of Leishmania promastigote forms and for cytotoxic activity against Kb and Vero cells. Compound (5) showed good activity against the Leishmania species tested, while all three compounds displayed moderate activity in both Kb and Vero cells.     

Lung disease and PKCs

The lung offers a rich opportunity for development of therapeutic strategies focused on isozymes of protein kinase C (PKCs). PKCs are important in many cellular responses in the lung, and existing therapies for pulmonary disorders are inadequate. The lung poses unique challenges as it interfaces with air and blood, contains a pulmonary and systemic circulation, and consists of many cell types. Key structures are bronchial and pulmonary vessels, branching airways, and distal air sacs defined by alveolar walls containing capillaries and interstitial space. The cellular composition of each vessel, airway, and alveolar wall is heterogeneous. Injurious environmental stimuli signal through PKCs and cause a variety of disorders. Edema formation and pulmonary hypertension (PHTN) result from derangements in endothelial, smooth muscle (SM), and/or adventitial fibroblast cell phenotype. Asthma, chronic obstructive pulmonary disease (COPD), and lung cancer are characterized by distinctive pathological changes in airway epithelial, SM, and mucous-generating cells. Acute and chronic pneumonitis and fibrosis occur in the alveolar space and interstitium with type 2 pneumocytes and interstitial fibroblasts/myofibroblasts playing a prominent role. At each site, inflammatory, immune, and vascular progenitor cells contribute to the injury and repair process. Many strategies have been used to investigate PKCs in lung injury. Isolated organ preparations and whole animal studies are powerful approaches especially when genetically engineered mice are used. More analysis of PKC isozymes in normal and diseased human lung tissue and cells is needed to complement this work. Since opposing or counter-regulatory effects of selected PKCs in the same cell or tissue have been found, it may be desirable to target more than one PKC isozyme and potentially in different directions. Because multiple signaling pathways contribute to the key cellular responses important in lung biology, therapeutic strategies targeting PKCs may be more effective if combined with inhibitors of other pathways for additive or synergistic effect. Mechanisms that regulate PKC activity, including phosphorylation and interaction with isozyme-specific binding proteins, are also potential therapeutic targets. Key isotypes of PKC involved in lung pathophysiology are summarized and current and evolving therapeutic approaches to target them are identified.     

Gender-related symptoms and correlates of alcohol dependence among men and women with a lifetime diagnosis of alcohol use disorders

This study explored gender-related symptoms and correlates of alcohol dependence in a crosssectional study of 150 men and 150 women with a lifetime diagnosis of alcohol use disorders (AUD). Participants were recruited in equal numbers from treatment settings, correctional centres and the general community. Standardized measures were used to determine participants' use of substances, history of psychiatric disorders and psychosocial stress, their sensation seeking and family history of substance use and mental health disorders. Multivariate analyses were used to detect patterns of variables associated with gender and the lifetime severity of AUD. Men had a longer history of severe AUD than women. Women had similar levels of alcohol dependence and medical and psychological sequelae as men, despite 6 fewer years of AUD. More women than men had a history of severe psychosocial stress, severe dependence on other substances and antecedent mental health problems, especially mood and anxiety disorders. There were differences in family history of alcohol-related problems approximating same-gender aggregation. The severity of a lifetime AUD was predicted by its earlier age at onset and the occurrence of other disorders, especially anxiety, among both men and women. The limitations in the generalizability of these findings due to sample idiosyncrasies are discussed.     

Biochemical and molecular characterisation of cubozoan protein toxins

Class Cubozoa includes several species of box jellyfish that are harmful to humans. The venoms of box jellyfish are stored and discharged by nematocysts and contain a variety of bioactive proteins that are cytolytic, cytotoxic, inflammatory or lethal. Although cubozoan venoms generally share similar biological activities, the diverse range and severity of effects caused by different species indicate that their venoms vary in protein composition, activity and potency. To date, few individual venom proteins have been thoroughly characterised, however, accumulating evidence suggests that cubozoan jellyfish produce at least one group of homologous bioactive proteins that are labile, basic, haemolytic and similar in molecular mass (42-46 kDa). The novel box jellyfish toxins are also potentially lethal and the cause of cutaneous pain, inflammation and necrosis, similar to that observed in envenomed humans. Secondary structure analysis and remote protein homology predictions suggest that the box jellyfish toxins may act as α-pore-forming toxins. However, more research is required to elucidate their structures and investigate their mechanism(s) of action. The biological, biochemical and molecular characteristics of cubozoan venoms and their bioactive protein components are reviewed, with particular focus on cubozoan cytolysins and the newly emerging family of box jellyfish toxins.     

Dose tolerability of chronically inhaled voriconazole solution in rodents

Invasive pulmonary aspergillosis (IPA) is a fungal disease of the lung associated with high mortality rates in immunosuppressed patients despite treatment. Targeted drug delivery of aqueous voriconazole solutions has been shown in previous studies to produce high tissue and plasma drug concentrations as well as improved survival in a murine model of IPA. In the present study, rats were exposed to 20 min nebulizations of normal saline (control group) or aerosolized aqueous solutions of voriconazole at 15.625 mg (low dose group) or 31.25 mg (high dose group). Peak voriconazole concentrations in rat lung tissue and plasma after 3 days of twice daily dosing in the high dose group were 0.85 ± 0.63 μg/g wet lung weight and 0.58 ± 0.30 μg/mL, with low dose group lung and plasma concentrations of 0.38 ± 0.01 μg/g wet lung weight and 0.09 ± 0.06 μg/mL, respectively. Trough plasma concentrations were low but demonstrated some drug accumulation over 21 days of inhaled voriconazole administered twice daily. Following multiple inhaled doses, statistically significant but clinically irrelevant abnormalities in laboratory values were observed. Histopathology also revealed an increase in the number of alveolar macrophages but without inflammation or ulceration of the airway, interstitial changes, or edema. Inhaled voriconazole was well tolerated in a rat model of drug inhalation.